research use only

Relebactam β-lactamase inhibitor

Name: Relebactam
Brand: Selleck Chemicals
SKU: S0074
Availability: InStock
Rating: 5 (1 reviews)

Cat.No.S0074

Relebactam (MK-7655) is a potent inhibitor against KPC-2, class A and class C (AmpC) β-lactamases.

Chemical Structure

Molecular Weight: 348.38

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability Specificity

Quality Control

Batch: Purity: 99.75%

99.75

Related Targets	Immunology & Inflammation related CD markers Interleukins Anti-infection Antioxidant COX Histamine Receptor TNF-alpha ROS Parasite PD-1/PD-L1 TLR Prostaglandin Receptor IFN CXCR Nrf2 NOS CCR NLRP3 eIF STING AhR IL Receptor Complement System IRAK IDO/TDO PGES NADPH-oxidase FKBP LTR

Chemical Information, Storage & Stability

Molecular Weight	348.38	Formula	C₁₂H₂₀N₄O₆S	Storage (From the date of receipt)	3 years -20°C powder
CAS No.	1174018-99-5	--		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	MK-7655			Smiles	C1CC(N2CC1N(C2=O)OS(=O)(=O)O)C(=O)NC3CCNCC3

Solubility

In vitro
Batch:

DMSO : 70 mg/mL ( (200.93 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : 70 mg/mL

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	3.5mg/ml (10.05mM)	Taking the 1 mL working solution as an example, add 50 μL of 70 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.5mg/ml (1.44mM)	Taking the 1 mL working solution as an example, add 50 μL of 10 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC₅₀/Ki	β-lactamase ^[1]
References	https://pubmed.ncbi.nlm.nih.gov/29610205/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT05561764	Recruiting	Cystic Fibrosis\|Pneumonia Bacterial	Hartford Hospital\|Merck Sharp & Dohme LLC\|Q2 Solutions\|Connecticut Children''s Medical Center\|St. Christopher''s Hospital for Children\|University of Texas Southwestern Medical Center\|University of Pittsburgh Medical Center\|Indiana University Health Methodist Hospital\|James Whitcomb Riley Hospital for Children	January 3 2023	Phase 4
NCT05146154	Enrolling by invitation	Obesity\|Critical Illness	University of Illinois at Chicago\|Merck Sharp & Dohme LLC	January 1 2023	Phase 4
NCT05285046	Unknown status	Bacterial Infections\|Antibiotic Resistant Infection	D''Or Institute for Research and Education	April 1 2022	--
NCT04493151	Completed	Sepsis	Joseph L. Kuti PharmD\|Merck Sharp & Dohme LLC\|Hartford Hospital	January 1 2021	Phase 1
NCT04147221	Completed	Sepsis	Hartford Hospital\|Merck Sharp & Dohme LLC	February 10 2020	Phase 1
NCT03969901	Active not recruiting	Suspected or Documented Gram-negative Bacterial Infection	Merck Sharp & Dohme LLC	October 8 2019	Phase 2\|Phase 3

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):